Skip to main content

Table 1 Characteristics of articles included in the meta-analysis

From: Dexamethasone and compliance affect TTFields efficacy to glioblastoma patients: a systematic review and meta-analysis

Study ID, year Journal Country Study design Intervention Patients, n Median age Male, (n%) Median OS (months)
T C T C T C
Mrugala 2014 [21] Seminars In Oncology USA Retrospective TTFields with compliance ≥ 75% TTFields with compliance < 75% 127 160 55 (18~86) 13.5 4.0
Stupp 2017 [18] JAMA Multinati-onal RCT TTFields with compliance ≥ 75% TTFields with compliance < 75% 265 185 56 (19~83) 316 (68%) 22.6 19.1
Kanner 2014 [31] Seminars In Oncology Israel Post hoc analysis TTFields with compliance ≥ 75% TTFields with compliance < 75% 92 28 54 (24~80) 92 (77%) 7.7 4.5
Wong 2014 [16] Cancer Med USA Post hoc analysis TTFields with daily dexamethasone ≤ 4.1 mg TTFields with daily dexamethasone > 4.1 mg 14 106 54 24.8 6.2
Wong 2015 [14] British Joutnal Of Cancer USA Post hoc analysis TTFields with daily dexamethasone ≤ 4.1 mg TTFields with daily dexamethasone > 4.1 mg 56 65 54 (24~80) 92 (77%) 11.0 4.8